KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms
Medical Oncology · 20.08.2026 · 43 (9)
DOI: 10.1007/s12032-026-03318-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 20.08.2026. Verfasst von Akhil Kapoor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
KRAS mutations represent the most common oncogenic driver in Western NSCLC and a major therapeutic challenge historically deemed "undruggable." The approval of allele-specific KRAS G12C inhibitors has transformed management, yet overall survival gains remain modest and resistance is inevitable. Rapid advances in next-generation KRAS inhibitors, rational combinations, and mutant-specific strategies (G12D, G12V) necessitate an updated synthesis of evolving evidence. To critically review the therapeutic landscape of KRAS-mutant NSCLC, covering biological underpinnings, clinical efficacy of approved and investigational inhibitors, mechanisms of resistance, combination strategies, and emerging paradigms likely to redefine future standards of care. A comprehensive narrative review of published clinical trials, translational studies, resistance-mechanism analyses, and real-world datasets focusing on KRAS-mutant NSCLC. Key sources include phase I-III trials of sotorasib, adagrasib, next-generation G12C inhibitors, mutant-specific G12D inhibitors, and ongoing combination studies integrating KRAS blockade with immunotherapy, MAPK-axis inhibitors, SHP2/SOS1 inhibitors, EGFR/MET inhibitors, and chemotherapy. Sotorasib and adagrasib achieve ORRs of 37-43% and median PFS ~ 6-7 months in previously treated KRAS G12C NSCLC, with improved tolerability over docetaxel. Next-generation inhibitors (olomorasib, divarasib, glecirasib, D-1553, IBI351) demonstrate ORRs 45-55% and, in some studies, PFS exceeding first-generation agents, while emerging KRAS G12D inhibitors show early proof-of-concept activity. Resistance arises through on-target KRAS alterations, RTK-RAS bypass signaling, MAPK/PI3K pathway reactivation, and co-mutation-driven phenotypic remodeling. Combination strategies-particularly KRAS inhibitor + PD-1 blockade, SHP2/SOS1 inhibition, EGFR/MET inhibition, or platinum doublets-are yielding higher response rates and deeper, more durable suppression in early trials. KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset. Future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, 221005, India.
- Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, 221005, India. dr.anuj.gupta24@gmail.co…
- Cancer Genetics, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
- Biostatistics, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
- Departments of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.
- Molecular Pathology, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.
ORCID-Profile: Anuj Gupta
Zitieren
APA
Kapoor, A., Sansar, B., Gupta, A., Mishra, B. K., Rungta, A., Pal, A., Srivastava, S., Shah, M., Menon, N., Pai, T., Shetty, O., Chandrani, P., Choughule, A., Noronha, V., & Prabhash, K. (2026). KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. Medical Oncology, 43(9). https://doi.org/10.1007/s12032-026-03318-2
Vancouver
Kapoor A, Sansar B, Gupta A, Mishra BK, Rungta A, Pal A, et al. KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. Medical Oncology. 2026;43(9). doi:10.1007/s12032-026-03318-2
BibTeX
@article{Kapoor2026,
author = {Kapoor, Akhil and Sansar, Bipinesh and Gupta, Anuj and Mishra, Bal Krishna and Rungta, Archi and Pal, Ankita and Srivastava, Shreya and Shah, Minit and Menon, Nandini and Pai, Trupti and Shetty, Omshree and Chandrani, Pratik and Choughule, Anuradha and Noronha, Vanita and Prabhash, Kumar},
title = {KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {9},
doi = {10.1007/s12032-026-03318-2}
}
EUVIMED